Amgen (NSDQ:AMGN) announced today that it successfully completed its $1.9 billion acquisition of Five Prime Therapeutics (NSDQ:FPRX). Thousand Oaks, Calif.-based Amgen has officially acquired South San Francisco-based Five Prime for $38 per share in cash, reaching an equity value of approximately $1.9 billion. The acquisition was initially announced on March 4, 2021. As of the […]
Pharmaceuticals
Oncopeptides seeks EU marketing authorization for multiple myeloma treatment
Oncopeptides announced today that it submitted an application for European marketing authorization of its melflufen therapeutic. Conditional marketing authorization from the European Medicines Agency (EMA) is the aim for the company after its pivotal phase 2 Horizon study provided positive outcomes with melflufen (melphalan flufenamide) in treating relapsed refractory multiple myeloma, according to a news […]
Horizon touts data from trials for thyroid eye disease infusion treatment
Horizon Therapeutics announced today that study results highlight the success of its Tepezza infusion for treating thyroid eye disease. Dublin, Ireland-based Horizon’s Tepezza proved in pooled Phase 2 and Phase 3 clinical trial data that it significantly improves proptosis (eye bulging) and diplopia (double vision) for TED patients in different subgroups, with most maintaining a […]
CeQur raises $115M for wearable insulin delivery device
CeQur announced today that it closed an oversubscribed equity financing round with proceeds of $115 million. Lucerne, Switzerland/Marlborough, Mass.–based CeQur said in a news release that it plans to use the funds to advance the commercial plans for the CeQur Simplicity wearable insulin delivery device. The company’s plans include market development, a phased commercial launch […]
Terumo launches therapeutic interventional oncology team
Terumo (TSE: 4543) announced that it has launched a global therapeutic interventional oncology team, effective April 1, 2021. Leuven, Belgium-based Terumo said in a news release that team’s introduction reflects its aspiration to be a global leader in the interventional oncology space by focusing on improving quality of life and survival. Team members work in […]
GH Research closes $125M oversubscribed Series B
GH Research Ireland announced that it closed an oversubscribed Series B financing round with proceeds of $125 million. Dublin, Ireland-based GH develops the GH001 therapeutic, a drug product for 5-MeO-DMT administration through a proprietary inhalation approach. A Phase 1 healthy volunteer trial showed GH001 to be well-tolerated while defining a dose range and individualized dosing […]
Genentech wins FDA approval for Xolair prefilled syringe
Genentech announced today that the FDA approved its supplemental biologics license application for the Xolair prefilled syringe. South San Francisco-based Genentech touts the Xolair (omalizumab) prefilled syringe for self-injection across all approved U.S. indications as the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for treating moderate to severe persistent allergic asthma, […]
Teva Pharmaceuticals receives European approval for Spiromax inhalers
Teva Pharmaceuticals announced today that it received European marketing authorization for its Seffalair and BroPair Spiromax inhalers. Seffalair Spiromax and its duplicate BroPair Spiromax (salmeterol xinafoate/ fluticasone propionate, 12.75/100 and 12.75/202 micrograms delivered doses) received approval as a maintenance treatment for asthma in adults and adolescents aged 12 years and older, according to a news […]
Intravacc touts preclinical, non-human results for COVID-19 nasal spray vaccine
Intravacc is today touting positive pre-clinical results of its SARS-CoV-2 nasal spray vaccine candidate in non-human subjects. Bilthoven, Netherlands-based Intravacc’s SARS-CoV-2 outer membrane vesicle (OMV)-based recombinant spike protein (rSp) nasal spray candidate was observed in four groups of mice and four groups of hamsters, all of which received two intranasal immunizations on day one and […]
Kindeva, Cambridge Healthcare Innovations to collaborate on dry-powder inhaler
Kindeva Drug Delivery and Cambridge Healthcare Innovations announced a collaboration to commercialize the latter’s dry-powder inhaler. St. Paul, Minn.-based Kindeva is set to use its product development, regulatory affairs and manufacturing capabilities to help develop and commercialize CHI’s Aeolus dry-powder inhaler (DPI) platform technology, according to a news release. Under the agreement, Kindeva will lead […]
